Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - frailty

MedXY AI/MedXY News/Tag: frailty

MedXY News

EnglishTag

frailty

24 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology critical care public health artificial intelligence Alzheimer's disease breast cancer diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

Metabolomic Clock Links Plasma Metabolites to Ageing, Frailty, and Cognitive Decline

Diabetes & Endocrinologymetabolomicsageing

Metabolomic Clock Links Plasma Metabolites to Ageing, Frailty, and Cognitive Decline

By MedXY|Jul 26, 2026

A metabolomic clock based on plasma metabolites accurately estimated chronological age (r=0.92) and was associated with mortality, frailty, and cognitive impairment across two European cohorts.

Frailty Linked to 2–3 Year Earlier Dementia Diagnosis, Especially in Those With Low Brain Pathology

Neurologyfrailtydementia

Frailty Linked to 2–3 Year Earlier Dementia Diagnosis, Especially in Those With Low Brain Pathology

By MedXY|Jul 26, 2026

Frailty was associated with a 3.6% younger age at dementia diagnosis (about 2–3 years earlier) in a 23-year longitudinal study. The link was strongest in men and in participants with low neuropathologic burden.

Switching from Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients with Atrial Fibrillation: Insights from a Korean Nationwide Study

CardiologyanticoagulationAsian Population

Switching from Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients with Atrial Fibrillation: Insights from a Korean Nationwide Study

By MedXY|Jul 3, 2026

In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.

ICU Readmission Raises 60-Day Mortality Substantially Regardless of Frailty, but Frail Patients Carry the Highest Absolute Risk

Critical Care60-day mortalityANZICS

ICU Readmission Raises 60-Day Mortality Substantially Regardless of Frailty, but Frail Patients Carry the Highest Absolute Risk

By MedXY|May 22, 2026

In a binational registry study of 615,719 ICU admissions, ICU readmission was linked to a similar absolute increase in 60-day mortality in frail and nonfrail patients, although frail readmitted patients had the highest overall mortality.

Strengthening the Frail: Multimodal Prehabilitation and Clinical Resilience in Geriatric Gastric Cancer Surgery

Clinical UpdatesERASfrailty

Strengthening the Frail: Multimodal Prehabilitation and Clinical Resilience in Geriatric Gastric Cancer Surgery

By MedXY|Apr 2, 2026

This review synthesizes evidence from the GISSG+2201 trial and related studies, demonstrating that supervised multimodal prehabilitation significantly reduces postoperative complications and enhances functional recovery in older, frail pati

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

Cardiologycardiovascular riskESPRIT Trial

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

By MedXY|Jan 16, 2026

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv

Beyond Glucose: SGLT-2 Inhibitors and GLP-1 Receptor Agonists Slow Frailty Progression in Older Adults

Diabetes & EndocrinologyfrailtyGLP-1 receptor agonists

Beyond Glucose: SGLT-2 Inhibitors and GLP-1 Receptor Agonists Slow Frailty Progression in Older Adults

By MedXY|Dec 30, 2025

A large-scale Medicare study suggests that SGLT-2 inhibitors and GLP-1 receptor agonists significantly slow frailty progression in older adults with type 2 diabetes, independent of their cardiovascular benefits, marking a potential shift in

Beyond Chronological Age: How Frailty Dictates Survival and Functional Recovery After Out-of-Hospital Cardiac Arrest

CardiologyCardiologycritical care

Beyond Chronological Age: How Frailty Dictates Survival and Functional Recovery After Out-of-Hospital Cardiac Arrest

By MedXY|Dec 28, 2025

A secondary analysis of the TTM2 trial reveals that frailty is a potent predictor of mortality and poor neurological outcomes after out-of-hospital cardiac arrest, with severely frail patients facing a 35-fold higher risk of poor functional

Coronary Revascularization in Older Adults: Key Recommendations from the 2025 AHA Scientific Statement

CardiologyAHA guidelinecoronary revascularization

Coronary Revascularization in Older Adults: Key Recommendations from the 2025 AHA Scientific Statement

By MedXY|Dec 25, 2025

The 2025 AHA scientific statement provides practical, patient-centered guidance for coronary revascularization in older adults, emphasizing geriatric assessment, individualized strategy selection, and shared decision-making.

Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort

Critical Carecritical carefrailty

Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort

By MedXY|Dec 10, 2025

In a 497,185‑patient registry study, frailty (CFS ≥5) was common and associated with substantially higher in‑hospital mortality across all severities of acute hypoxemic respiratory failure (AHRF). The relationship between PaO2/FiO2 and deat

Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT

Anesthesiologyfrailtyperioperative care

Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT

By MedXY|Dec 9, 2025

A pragmatic multicenter randomized trial found that coach-supported, home-based multimodal prehabilitation before elective noncardiac surgery did not reduce 30-day postoperative disability or in-hospital complications in older adults with f

Stepping Down Antihypertensives in Frail Nursing-Home Residents Did Not Reduce Mortality: Results from the RETREAT-FRAIL Trial

Cardiologyantihypertensive deprescribingfrailty

Stepping Down Antihypertensives in Frail Nursing-Home Residents Did Not Reduce Mortality: Results from the RETREAT-FRAIL Trial

By MedXY|Dec 6, 2025

In the RETREAT-FRAIL randomized trial of nursing-home residents ≥80 years with systolic BP <130 mm Hg, a protocolized step-down of antihypertensive drugs reduced medication burden and raised systolic BP modestly but did not change all-ca

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Cardiologyejection fractionFINEARTS-HF

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY|Dec 3, 2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a

Frailty after Acute Myocardial Infarction: A Stronger Predictor of 1‑Year Death in Younger Patients Than in the Elderly

Cardiologyacute myocardial infarctionfrailty

Frailty after Acute Myocardial Infarction: A Stronger Predictor of 1‑Year Death in Younger Patients Than in the Elderly

By MedXY|Dec 2, 2025

A large population study shows frailty is independently linked to worse 1‑year outcomes after AMI across ages, with the largest relative impact in patients under 55 — underscoring the need to assess frailty beyond geriatric populations.

Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters

Hematology-OncologyCLLdose intensity

Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters

By MedXY|Nov 14, 2025

Large trial and real‑world data show fixed‑duration venetoclax‑obinutuzumab delivers high response and durable PFS in fit and unfit CLL patients; maintaining adequate venetoclax dose intensity appears important for MRD and long‑term outcome

Extending the Hospital Frailty Risk Score to All Adults: Implications for Hospital Stay, Mortality, and Costs in England

Internal MedicinefrailtyHospital Frailty Risk Score

Extending the Hospital Frailty Risk Score to All Adults: Implications for Hospital Stay, Mortality, and Costs in England

By MedXY|Oct 20, 2025

The Hospital Frailty Risk Score (HFRS) predicts length of stay, mortality, and costs across all adult age groups in England, with stronger effects in older adults, supporting broader clinical use beyond the elderly.

Unveiling Frailty in England’s Homeless Population: Socioeconomic Insights and Health Implications

Internal Medicinefrailtyhomelessness

Unveiling Frailty in England’s Homeless Population: Socioeconomic Insights and Health Implications

By MedXY|Oct 20, 2025

A large-scale analysis reveals high frailty prevalence among people experiencing homelessness in England, highlighting critical socioeconomic factors influencing vulnerability.

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

Hematology-OncologydaratumumabDexamethasone

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY|Oct 15, 2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

CardiologyFINEARTS-HFfinerenone

Finerenone Efficacy and Safety Across Frailty Levels in Heart Failure: Insights from the FINEARTS-HF Trial

By MedXY|Oct 7, 2025

This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFp

Reevaluating Antihypertensive Therapy in Frail Elderly Nursing Home Residents: Insights from the RETREAT-FRAIL Trial

Cardiologyantihypertensive therapyelderly

Reevaluating Antihypertensive Therapy in Frail Elderly Nursing Home Residents: Insights from the RETREAT-FRAIL Trial

By MedXY|Oct 5, 2025

The RETREAT-FRAIL trial found no survival benefit from progressively reducing antihypertensive medications in frail nursing home residents aged ≥80 with controlled blood pressure, supporting individualized treatment strategies.

Ask MedXY AI

Most popular

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Family Medicine & Nutrition

The Curious Scent of Feces: The Dual Identity and Health Secrets of Skatole

Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Family Medicine & Nutrition

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications